Essais liés9clinical trials
VilleFreiburg im Breisgaulocalisation
PaysGermanylocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT07282574

Ouvrir le site du centre

Essais cliniques associés

9
MoléculeIndication / populationPhaseNCTTitreStatut
Epcoritamab SEP Phase 2 NCT05660967 EPCORE DLBCL-3 — Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma TERMINATED
RO7268489 SEP Phase 2 NCT07282574 Mintaka — A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) RECRUITING
BIIB017 (peginterferon beta-1a) SEP Phase 3 NCT03958877 A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis ACTIVE_NOT_RECRUITING
Lasmiditan Migraine Phase 3 NCT04396236 PIONEER-PEDS1 — A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine TERMINATED
Elranatamab Cancer Phase 3 NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) RECRUITING
Inotuzumab ozogamicin Cancer Phase 2 NCT05748171 A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL RECRUITING
Lasmiditan Migraine Phase 3 NCT04396574 PIONEER-PEDS2 — A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine TERMINATED
Givinostat Myopathies Phase 3 NCT05933057 ULYSSES — Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy RECRUITING
Drisapersen Myopathies À vérifier NCT02636686 Extension Study of Drisapersen in DMD Subjects NO_LONGER_AVAILABLE